Longeveron (LGVN) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Longeveron is the larger company by market cap ($5.6 million vs $5.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LGVN | TOVX |
|---|---|---|
| Share price | $1.66 | $0.12 |
| Market cap | $5.60M | $5.51M |
| 1-day change | -8.79% | -6.25% |
| YTD return | — | -42.86% |
| 1-year return | — | -45.45% |
| 5-year return | — | -99.86% |
| P/E ratio (TTM) | — | 0.10 |
| EPS (TTM) | $-7.95 | $1.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.20M | — |
| Revenue growth (YoY) | -49.87% | — |
| Net income (latest FY) | $-22.70M | $-23.74M |
| Gross margin | 66.97% | — |
| Operating margin | -1942.20% | — |
| Net margin | -1893.58% | — |
| 52-week high | $12.30 | $0.49 |
| 52-week low | $1.31 | $0.12 |
| Distance from 52-week high | -86.50% | -75.51% |
| Analyst consensus | none | none |
| Avg. price target upside | +3589.76% | +1983.33% |
| Average volume | 115.35K | 2.02M |
| Shares outstanding | 3.23M | 45.89M |
| Employees | 38 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Longeveron
LGVN stock →Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
LGVN vs TOVX FAQ
Which is bigger, Longeveron or Theriva Biologics?
Longeveron (LGVN) is larger, with a market capitalization of $5.60M compared with $5.51M for Theriva Biologics (TOVX).
Are Longeveron and Theriva Biologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.